ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

by palligoelme@gmail.com | Jun 10, 2025 | Clinical Trials

​ Conditions: Atopic Dermatitis; Atopic; Dermatitis; AD; Eczema Interventions: Drug: ATI-045; Drug: Placebo Sponsors: Aclaris Therapeutics, Inc. Recruiting Conditions: Atopic Dermatitis; Atopic; Dermatitis; AD; Eczema Interventions: Drug: ATI-045; Drug: Placebo...

Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health

by palligoelme@gmail.com | Jun 9, 2025 | Clinical Trials

​ Conditions: HIV Prevention; Sexual Health Interventions: Behavioral: Intervention; Behavioral: Control Sponsors: Rhode Island Hospital; National Institute of Mental Health (NIMH) Recruiting Conditions: HIV Prevention; Sexual Health Interventions: Behavioral:...

A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

by palligoelme@gmail.com | Jun 9, 2025 | Clinical Trials

​ Conditions: Colon Cancer; Rectal Cancer; Colorectal Cancer; Colorectal Cancer (CRC) Interventions: Drug: fruquintinib; Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Sponsors: SCRI Development Innovations, LLC; Takeda Development Center Americas, Inc....

Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic TNBC

by palligoelme@gmail.com | Jun 9, 2025 | Clinical Trials

​ Conditions: Metastatic Triple-Negative Breast Cancer Interventions: Drug: Sacituzumab govitecan; Drug: Naxitamab Sponsors: M.D. Anderson Cancer Center; Y-mAbs Therapeutics Not yet recruiting Conditions: Metastatic Triple-Negative Breast Cancer Interventions: Drug:...

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

by palligoelme@gmail.com | Jun 9, 2025 | Clinical Trials

​ Conditions: Obesity Interventions: Drug: CagriSema (Cagrilintide B and Semaglutide I); Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Sponsors: Novo Nordisk A/S Not yet recruiting Conditions: Obesity Interventions: Drug: CagriSema...